A review of cardiovascular benefits of SGLT2 inhibitors

被引：4

作者：

Zhang, Yingxia ^{[1
]}

Han, Qinghua ^{[2
]}

机构：

[1] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Clin Med 1, Minist Educ, Taiyuan, Shanxi, Peoples R China

[2] Shanxi Med Univ, Key Lab Cellular Physiol, Dept Cardiol, Minist Educ,Hosp 1, 85 South Jiefang Rd, Taiyuan 030001, Shanxi, Peoples R China

来源：

MEDICINE | 2022年 / 101卷 / 36期

关键词：

arrhythmia; cardiomyopathy; heart failure; hypertension; mechanism; myocardial infarction; sodium-glucose cotransporter 2 inhibitor; MYOCARDIAL-INFARCTION; DOUBLE-BLIND; EMPAGLIFLOZIN; DAPAGLIFLOZIN; RISK; CARDIOPROTECTION; CANAGLIFLOZIN; ASSOCIATION; DISEASES; DEATH;

D O I：

10.1097/MD.0000000000030310

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Sodium-glucose cotransporter 2 inhibitor (SGLT2I) is a new type of hypoglycemic drug that targets the kidney. As research continues to advance on this topic, it has been found that SGLT2I has multiple protective effects, such as hypoglycemic, cardio-renal protective, antihypertensive, and lipid-lowering effects. This review discusses the current concepts and possible mechanisms of SGLT2I in the treatment of heart failure, myocardial infarction, hypertension, cardiomyopathy and arrhythmia to provide a reference for clinicians to use drugs more reasonably and scientifically.

引用

页数：5

共 61 条

[1] 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2021 [J].

不详 .

DIABETES CARE, 2021, 44 :S125-S150

[2] Empagliflozin in Heart Failure with a Preserved Ejection Fraction [J].

Anker, Stefan D. ;

Butler, Javed ;

Filippatos, Gerasimos ;

Ferreira, Joao P. ;

Bocchi, Edimar ;

Boehm, Michael ;

Brunner-La Rocca, Hans-Peter ;

Choi, Dong-Ju ;

Chopra, Vijay ;

Chuquiure-Valenzuela, Eduardo ;

Giannetti, Nadia ;

Gomez-Mesa, Juan Esteban ;

Janssens, Stefan ;

Januzzi, James L. ;

Gonzalez-Juanatey, Jose R. ;

Merkely, Bela ;

Nicholls, Stephen J. ;

Perrone, Sergio V. ;

Pina, Ileana L. ;

Ponikowski, Piotr ;

Senni, Michele ;

Sim, David ;

Spinar, Jindrich ;

Squire, Iain ;

Taddei, Stefano ;

Tsutsui, Hiroyuki ;

Verma, Subodh ;

Vinereanu, Dragos ;

Zhang, Jian ;

Carson, Peter ;

Lam, Carolyn Su Ping ;

Marx, Nikolaus ;

Zeller, Cordula ;

Sattar, Naveed ;

Jamal, Waheed ;

Schnaidt, Sven ;

Schnee, Janet M. ;

Brueckmann, Martina ;

Pocock, Stuart J. ;

Zannad, Faiez ;

Packer, Milton .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (16) :1451-1461

[3] Sodium-glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy [J].

Arow, M. ;

Waldman, M. ;

Yadin, D. ;

Nudelman, V. ;

Shainberg, A. ;

Abraham, N. G. ;

Freimark, D. ;

Kornowski, R. ;

Aravot, D. ;

Hochhauser, E. ;

Arad, M. .

CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)

[4]

McDonagh Theresa A, 2022, Rev Esp Cardiol (Engl Ed), V75, P523, DOI [10.1002/ejhf.2333, 10.1093/eurheartj/ehab368, 10.1016/j.rec.2022.05.005]

[5] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits [J].

Baartscheer, Antonius ;

Schumacher, Cees A. ;

Wust, Rob C. I. ;

Fiolet, Jan W. T. ;

Stienen, Ger J. M. ;

Coronel, Ruben ;

Zuurbier, Coert J. .

DIABETOLOGIA, 2017, 60 (03) :568-573

[6] Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure [J].

Bhatt, Deepak L. ;

Szarek, Michael ;

Steg, P. Gabriel ;

Cannon, Christopher P. ;

Leiter, Lawrence A. ;

McGuire, Darren K. ;

Lewis, Julia B. ;

Riddle, Matthew C. ;

Voors, Adriaan A. ;

Metra, Marco ;

Lund, Lars H. ;

Komajda, Michel ;

Testani, Jeffrey M. ;

Wilcox, Christopher S. ;

Ponikowski, Piotr ;

Lopes, Renato D. ;

Verma, Subodh ;

Lapuerta, Pablo ;

Pitt, Bertram .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (02) :117-128

[7] Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study [J].

Bouchi, Ryotaro ;

Terashima, Masahiro ;

Sasahara, Yuriko ;

Asakawa, Masahiro ;

Fukuda, Tatsuya ;

Takeuchi, Takato ;

Nakano, Yujiro ;

Murakami, Masanori ;

Minami, Isao ;

Izumiyama, Hajime ;

Hashimoto, Koshi ;

Yoshimoto, Takanobu ;

Ogawa, Yoshihiro .

CARDIOVASCULAR DIABETOLOGY, 2017, 16

[8] A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial [J].

Brown, Alexander J. M. ;

Gandy, Stephen ;

McCrimmon, Rory ;

Houston, John Graeme ;

Struthers, Allan D. ;

Lang, Chim C. .

EUROPEAN HEART JOURNAL, 2020, 41 (36) :3421-3432

[9] Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension [J].

Cefalu, William T. ;

Leiter, Lawrence A. ;

de Bruin, Tjerk W. A. ;

Gause-Nilsson, Ingrid ;

Sugg, Jennifer ;

Parikh, Shamik J. .

DIABETES CARE, 2015, 38 (07) :1218-1227

[10] Atrial fibrillation in patients with diabetes: molecular mechanisms and therapeutic perspectives [J].

De Sensi, Francesco ;

De Potter, Tom ;

Cresti, Alberto ;

Severi, Silva ;

Breithardt, Guenter .

CARDIOVASCULAR DIAGNOSIS AND THERAPY, 2015, 5 (05) :364-373

← 1 2 3 4 5 6 7 →